Application of Temozolomide (CAS: 85622-93-1)

I. Core Clinical Pharmaceutical Application

Glioblastoma (GBM)

• Newly diagnosed glioblastoma multiforme: Administered concurrently with radiotherapy during chemoradiotherapy phase, followed by single-agent adjuvant chemotherapy, constituting the standard first-line treatment regimen for adult glioblastoma.
• Recurrent/refractory glioblastoma: Preferred single-agent salvage chemotherapy after failure of prior chemotherapy regimens.

Anaplastic Astrocytoma

Other Central Nervous System Malignancies

Clinical Trial Exploration for Solid Tumors

II. Industrial Application as Pharmaceutical Raw Material

• Pharmaceutical Formulation Production: The bulk drug is mainly processed into temozolomide capsules (dominant marketed dosage form); several pharmaceutical enterprises develop dry suspension for pediatric brain tumor patients or those with swallowing difficulties.
• R&D Raw Material for Pharmaceutical Development: Serves as control drug for pharmacological tests and screening material for combined medication research, applied in new drug screening, in vitro anti-tumor efficacy assays and pharmacology & toxicology studies by pharmaceutical manufacturers.

III. Application in Scientific Research

• Pharmacological Research: Utilized on in vitro glioma cell models to investigate anti-tumor mechanisms, drug resistance pathways and synergistic medication targets.
• In Vivo Animal Model Research: Dosed on orthotopic intracranial tumor-bearing animal models to assess synergistic anti-tumor efficacy of novel targeted medicines and radiotherapy sensitizers.
• Reference Standard for Pharmaceutical Analysis: Employed by pharmaceutical inspection institutions as official reference substance for assay determination and related substance testing.

   

  Contact information:

  Contact: Sophia Li

  Email: sophia@coreychem.com